Understanding the DEXA Study on GLP 1 and Diet
Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes mellitus and obesity. However, recent studies have raised concerns about the potential risks of GLP-1 medications on bone health and skeletal disorders, such as osteoporosis.
What is GLP-1 and How Does it Affect the Body?
GLP-1 is a naturally occurring hormone in the body that helps regulate blood sugar levels and appetite. GLP-1 receptor agonists, such as semaglutide and liraglutide, mimic the action of GLP-1 to improve glucose control and reduce hunger. However, some studies have suggested that GLP-1 medications may increase the risk of osteoporosis and bone fractures in obese individuals.
DEXA Scans: A Measure of Body Composition
Dual-energy X-ray absorptiometry (DEXA) scans are a non-invasive imaging technique that allows healthcare providers to measure bone mineral density (BMD) and body composition. A DEXA scan can differentiate between bone tissue and soft tissue, providing a comprehensive understanding of body composition and tracking changes over time.
Understanding the Risks of GLP-1 Medications
Recent studies have suggested that GLP-1 medications may increase the risk of osteoporosis and bone fractures in obese individuals. A study published in the Journal of the American Medical Association (JAMA) found that GLP-1 medications were associated with a higher risk of osteoporosis and gout. Another study published in the British Medical Journal (BMJ) found that GLP-1 medications were linked to a higher risk of bone fractures and osteoporosis.
The Role of Diet and Lifestyle in GLP-1 Therapy
Disease-modifying therapies, such as GLP-1 receptor agonists, work in conjunction with lifestyle interventions, including diet and exercise, to manage type 2 diabetes and obesity. A well-balanced diet and regular physical activity can help mitigate the risks associated with GLP-1 medications, such as bone loss and weight regain.
Navigating the Relationship Between GLP-1 and Diet
The relationship between GLP-1 and diet is complex, and more research is needed to understand the long-term effects of GLP-1 medications on body composition and bone health. However, some studies suggest that a healthy diet and regular physical activity can help promote bone health and reduce the risk of osteoporosis in individuals taking GLP-1 medications.
Conclusion
While GLP-1 receptor agonists have revolutionized the treatment of type 2 diabetes and obesity, recent studies have raised concerns about the potential risks of these medications on bone health and skeletal disorders. Understanding the relationship between GLP-1 and diet is essential to mitigating these risks and promoting optimal bone health. By working closely with a healthcare provider, individuals can navigate the benefits and risks of GLP-1 therapy and make informed decisions about their treatment plan.
References
- Elsevier - Clinical Insight: Lifestyle factors for patients receiving GLP-1 and dual receptor agonists to manage weight (2025)
- Medical News Today - GLP-1 drugs: Are they safe for long-term use? (2026)
- GoodRx - The Health Journal - GLP-1 receptor agonist initiation for weight loss in overweight patients with osteoporosis and hypertension (2026)
- ScienceDirect - The effects of subcutaneous semaglutide on body composition in adults with overweight/obesity using dual energy X-ray absorptiometry (DEXA) (2025)
